Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia

CNS Drugs

Volumn 12, Issue 2, 1999, Pages 135-150

  Madhusoodanan, Subramoniam ^a,b   Brenner, Ronald ^a,b   Cohen, Carl I ^b  

^a ST JOHN S EPISCOPAL HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 ISOENZYME; DIGOXIN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUVOXAMINE; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; QUETIAPINE; QUINIDINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; TACRINE; THEOPHYLLINE; THIORIDAZINE; WARFARIN; ZIPRASIDONE;

AGITATION; CLINICAL TRIAL; CONFUSION; DEMENTIA; DISEASE ASSOCIATION; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HUMAN; HYPERSALIVATION; HYPOTENSION; LETHARGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEIZURE; SOMNOLENCE; TARDIVE DYSKINESIA;

EID: 0032833079     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912020-00006     Document Type: Review

References (67)

1. 1. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 Suppl.; 9-15
2. 2. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146: 577-87
3. 3. Drevets WC, Rubin EG. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer's type. Biol Psychiatry 1989; 25: 39-48
4. 4. Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 1991; 29 (3): 224-32
5. 5. Risse SC, Barnes R. Pharmacologic treatment of agitation associated with dementia. J Am Geriatric Soc 1986; 34: 368-76
6. 6. Raskind MA, Risse SC, Lampe TH. Dementia and antipsychotic drugs. J Clin Psychiatry 1987; 48 Suppl.: 16-8
7. 7. Devanand DP, Sackeim HA, Brown RP, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46: 854-7
8. 8. Schneider LS, Pollock VE, Lyness SA. A meta analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553-63
9. 9. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756-65
10. 10. Saltz BL, Kane JM, Woerner MG, et al. Prospective study of tardive dyskinesia in the elderly. Psychopharmacol Bull 1989; 25: 52-6
11. 11. Avorn J, Monane M, Everitt DE, et al. Clinical assessments of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Int Med 1994; 154: 1113-7
12. 12. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14 (2): 87-96
13. 13. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 1996; 124 (1-2): 57-73
14. 14. Kumar V. Use of atypical agents in geriatric patients: a review. Int J Geriatr Psychopharmacology 1997; 1: 15-23
15. 15. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995; 345 (8949): 557-62
16. 16. Physician's desk reference. 53rd ed. Montvale (NJ): Medical Economics Company, 1999
17. 17. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavior disruption. Am J Geriatr Psychiatry 1995; 3: 26-33
18. 18. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7
19. 19. Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56: 189-5
20. 20. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Intl Psychogeriatr 1992; 4: 187-95
21. 21. Kumar V. Use of atypical antipsychotic agents in geriatric patients: a review. Int J Ger Psychopharmacol 1997; 1: 15-23
22. 22. Diederich N, Keipes M, Graas M, et al. La clozapine dans le traitement des manifestations psychiatriques de la maladie de Parkinson [in French]. Rev Neurol (Paris) 1995; 151: 251-7
23. 23. Factor SA, Brown D, Molho ES, et al. Clozapine: a 2 year open trial in Parkinson's Disease patients with psychosis. Neurology 1994; 44: 544-6
24. 24. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's Disease. Neurology 1989; 39: 1219-21
25. 25. Sajatovic M, Verbanae P, Ramirez L, et al. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea [letter]. Neurology 1991; 41: 156
26. 26. Bonuccelli U, Ceravolo R, Maremmani C, et al. Clozapine in Huntington's chorea [letter]. Neurology 1994; 44: 821-3
27. 27. Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 1993; 5: 206-8
28. 28. Jeste DV, Eastham JF, Lacro JP, et al. Management of late life psychosis. J Clin Psychiatry 1996; 57 Suppl. 3: 39-45
29. 29. Lacro JP, Eastham JH, Jeste DV, et al. Newer antipsychotics and antidepressants for elderly people. Curr Opin Psychiatry 1996; 9: 290-3
30. 30. Auzou P, Ozsancak C, Hanocquin D, et al. Clozapine for the treatment of psychosis in Parkinson's Disease: a review. Acte Neurol Scand 1996; 94: 329-36
31. 31. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry 1998; 59 Suppl. 1: 5-10
32. 32. De Deyn PP, De Smedt G, Brecher M. Psychosis and behavioral disturbances in dementia: effects of risperidone in 969 patients [abstract]. Eur Neuropsychopharmacol 1998; 8: S217
33. 33. Jeste DV, Lacro, JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716-9
34. 34. Brecher M. Follow-up study of risperidone in the treatment of patients with dementia: interim results on tardive dyskinesia and dyskinesia severity [abstract NR342]. American Psychiatric Association Annual Meeting, New Research Program & Abstracts; 1998 May 30-Jun 4; Toronto, Ontario
35. 35. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychosis associated with schizophrenia, schizoaffective disorder, bipolar disorder or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56 (11): 514-8
36. 36. Jeanblanc W, Davis YB. Risperidone for treating dementia associated aggression [letter]. Am J Psychiatry 1995; 152 (8): 1239
37. 37. Kopala LC, Honer WG. The use of risperidone in severely demented patients with persistent vocalizations. Int J Geriatr Psychiatry 1997; 12: 73-7
38. 38. Goldberg RJ, Goldberg J. Risperidone for dementia related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatrics 1997; 9: 65-8
39. 39. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998; 6 (2): 127-35
40. 40. Zarate CA, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoeconomic study. J Clin Psychiatry 1997; 58: 7: 311-7
41. 41. Madhusoodanan S, Sunesh P, Brenner R, et al. Experience with the atypical antipsychotics risperidone and olanzapine in the elderly. Ann Clin Pschiatry. In press
42. 42. Marciniak BH, Guay DRP. Risperidone tolerability in the long-term care population. Consult Pharm 1995; 10: 1374-7
43. 43. Katz I, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107-15
44. 44. Lemmens P, De Deyn PP. Risperidone in the treatment of behavioral disturbances in dementia [abstract NR343]. American Psychiatric Association Annual Meeting, New Research Program & Abstracts; 1998 May 30-Jun 4; Toronto, Ontario
45. 45. Meco G, Allesandria A, Bonifati, V, et al. Risperidone for hallucinosis in levodopa-treated Parkinson's disease patients. Lancet 1994; 343: 1370-1
46. 46. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556-9
47. 47. Meco G, Bonifati V, Alessandria A, et al. Risperidone in Huntington's disease [letter]. Hum Psychopharmacol 1995; 10: 353-4
48. 48. Reveley MA, Dursum SM, Andrews HA. Comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study. J Psychopharmacol 1996; 10: 162-5
49. 49. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Ger Psychiatry 1998; 6 (4): 347-9
50. 50. Parsa MA, Szigethy E, Voci JM, et al. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol 1997; 17: 134-5
51. 51. Dallochia C, Buffa C, Tinelli C, et al. Effectiveness of risperidone in Huntington's chorea patients. J Clin Psychopharmacol 1999; 19: 101-3
52. 52. Curtis RC, Resch DS. A case of Pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. In press
53. 53. Alexopoulos GS, Silver JM, Kahn DA, et al. The Expert Consensus Guideline Series: treatment of agitation in older patients with dementia. Postgrad Med 1998; (special report): 1-88
54. 54. Beasley CM. Safety of olanzapine. J Clin Psychiatry Monogr Ser 1997; 15: 2: 19-21
55. 55. Berman I, Bayog RD, Wu C, et al. Cognitive effect of olanzapine [abstract NR532]. American Psychiatric Association Annual Meeting, New Research Program & Abstracts; 1998 May 30-Jun 4; Toronto, Ontario
56. 56. Sajatovic M, Perez D, Brescan D, et al. Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacol Bull. In press
57. 57. Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients [abstract]. Psychopharmacol Bull 1995; 31: 534
58. 58. Street J, Clark WS, Mitan S, et al. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease. American College of Neuropsychopharmacology 37th Annual Meeting; 1998 Dec 14-18; Las Croabas, Puerto Rico. Scientific abstracts: 223
59. 59. Arvanitis LA, Rak IW. Efficacy, safety and tolerability of Seroquel (quetiapine) in elderly subjects with psychotic disorders [abstract]. Schizophrenia Res 1997; 24: 196
60. 60. Seroquel (Quetiapine Fumarate) Professional information brochure. Zeneca, Pharmaceuticals, Wilmington (DE). SQ1066 Rev B 10/97
61. 61. Hellewell JSE, Hands DC, McKellar J. Seroquel®: an effective atypical antipsychotic with no greater EPS than placebo across the full dose range [abstract]. Schizophr Res 1998; 29 (1-2): 154
62. 62. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J. Clin Psychopharmacol 1995; 15 Suppl.: 365-445
63. 63. Meco G, Bedini L, Bonifati, V, et al. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia: a single blind crossover study vs. placebo. Curr Ther Res 1989; 46: 876-83
64. 64. Addington DE, Addington JM. Cost of novel antipsychotics in clinical practice [abstract NR545]. American Psychiatric Association Annual Meeting, New Research Program & Abstracts; 1998 May 30-Jun 4; Toronto, Ontario
65. 65. Nasrallah HA, Chan YC, Votolato NA. Higher cost of olanzapine compared with risperidone in acute psychotic relapse [abstract NR592]. American Psychiatric Association Annual Meeting, New Research Program & Abstracts; 1998 May 30-Jun; Toronto, Ontario
66. 66. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone and olanzapine. Clin Ther 1998; 20: 1203-17
67. 67. Preskorn SH, Baird S, 11.2 billion dollars: is it worth it? J Prac Psych Behav Hlth 1998; 4: 3163-71